Pharmacokinetics of an oral drug (Acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes

Journal of Clinical Pharmacology

Volumn 47, Issue 7, 2007, Pages 798-805

  Kellmeyer, Terrie A ^a   Kesty, Nicole C ^a   Wang, Yan ^b,c   Frias, Juan P ^b,c   Fineman, Mark S ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Animas Corp   (United States)

^c Former Amylin Employees ^*

Author keywords

Pharmacokinetics; Pramlintide; Type 2 diabetes

Indexed keywords

PARACETAMOL; PLACEBO; PRAMLINTIDE; AMYLOID; ANALGESIC AGENT; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELIXIR; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; LUNG TOXICITY; MALE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE DRUG DOSE; STOMACH EMPTYING; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG INTERACTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMYLOID; ANALGESICS, NON-NARCOTIC; AREA UNDER CURVE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; FEMALE; GASTRIC EMPTYING; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 34548030200     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007300949     Document Type: Article

References (36)

1. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet. 1992;339:1179-1180.
2. Young AA. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes. 1997;4:282-290.
3. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389-397.
4. Chapman I, Parker B, Doran S, et al. Low-dose pramlintide reduced food intake and meal duration in healthy, normal weight subjects. Obesity. In press.
5. 5. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41:577-583. (Pubitemid 28206829)
6. 6.SamsomM,SzarkaLA,CamilleriM,VellaA,ZinsmeisterAR,RizzaRA.Pramlintide, anamylinanalog,selectivelydelaysgastricemptying:potentialroleofgastricemptying. AmJPhysiolGastrointestLiverPhysiol.2000;278:G946-G951.(Pubitemid30439174)
7. 7. Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Mot. 2002;14:123-131. (Pubitemid 34451212)
8. 8. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analogue pramlintide corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002;51:636-641. (Pubitemid 34516520)
9. 9. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504-508. (Pubitemid 35192237)
10. 10. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48:838-848. (Pubitemid 40767975)
11. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin treated subjects with type 2 diabetes. Diabetes Technol Ther, 2002;4:51-61.
12. 12. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled study. Diabetes Care. 2003;26:784-790. (Pubitemid 36929344)
13. 13. Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003;26:1-8. (Pubitemid 36928987)
14. 14. Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003;26:3074-3079. (Pubitemid 37339501)
15. 15. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004;20:55-60. (Pubitemid 38196249)
16. Guthrie R, Karl DM, Wang Y, Lorenzi G. In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy (abstract). Diabetes. 2005;54(suppl 1):A118.
17. Karl DM, Wang Y, Lorenzi G, Freeman JS. In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 2 diabetes failing to achieve glycemic targets with insulin therapy (abstract). Diabetes. 2005;54(suppl 1):A12.
18. 18.GreiffJM,RowbothamD. Pharmacokineticdruginteractionswithgastrointestinalmotilitymodifyingagents. ClinPharmacokinet.1994;27:447-461.(Pubitemid24364787)
19. Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol. 1992;32: 725-731.
20. 20. Marathe PH, Wen Y, Norton J, Greene DS, Barbhaiya RH, Wilding IR. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2000;50: 325-332. (Pubitemid 30766004)
21. Lee HT, Lee YJ, Chung SJ, Shim CK. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats. Res Commun Mol Pathol Pharmacol. 2000;108:311-323.
22. 22.ColburnWA,GottliebAB,KodaJ,KoltermanOG. PharmacokineticsandpharmacodynamicsofAC137(25,28,29tripro-amylin,human) afterintravenousbolusandinfusiondosesinpatientswithinsulin-dependentdiabetes.J. ClinPharmacol.1996;36:13-24.(Pubitemid26060729)
23. 23.ClementsJA,HeadingRC,NimmoWS,PrescottLF. Kineticsofacetaminophenabsorptionandgastricemptyinginman.ClinPharmacolTher. 1978;24:420-431.(Pubitemid9059905)
24. Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinetics. 1982;7:93-107.
25. McGilveray IJ, Mattock GL. Some factors affecting the absorption of paracetamol. J Pharm Pharmacol. 1972;24:615-619.
26. Jaffe JM, Colaizzi JL, Barry H. Effects of dietary components on GI absorption of acetaminophen tablets in man. J. Pharmacol Sci. 1971;60:1646-1650.
27. 27. Rostami-Hodjegan A, Shiran MR, Ayesh R, et al. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate, I: a four-way crossover study to compare the concentrationtime profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. Drug Dev Ind Pharm. 2002;28:523-531. (Pubitemid 34680552)
28. Wessels JC, Koeleman HA, Boneschans B, Steyn HS. The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group. Int J Pharmacol Ther Toxicol. 1992;30:208-213.
29. 29. Gandia P, Bareille MP, Saivin S, et al. Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. J. Clin Pharmacol. 2003;43:1235-1243. (Pubitemid 37280795)
30. 30. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J. Clin Pharmacol. 2005;45:570-577. (Pubitemid 40562948)
31. Nimmo J, Heading RC, Tothill P, Prescott LF. Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption. Br Med J. 1973;1: 587-589.
32. 32. Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40:82-88. (Pubitemid 27035714)
33. Weyer C, Maggs DG, Kim D, et al. Mealtime amylin replacement with pramlintide markedly improves postprandial glucose excursions when added to regular insulin or insulin lispro in patients with type 1 diabetes: a dose-timing study. Diabetologia. 2002;45:A240.
34. 34. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J. Clin Pharmacol. 2005;45:1032-1037. (Pubitemid 41192362)
35. Kothare P, Linnebjerg H, Atkins M, Mace K, Mitchell M. Effect of exenatide on lisinopril pharmacodynamics in patients treated for hypertension (abstract). Clin Pharm Ther. 2005;77:PI-24.
36. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs. 2004;64:1419-1432.